According to GlobalData’s medical device pipeline database, 12 Positron Emission Tomography/Computed Tomography (PET/CT) Systems devices are in various stages of development globally. GlobalData’s report Positron Emission Tomography/Computed Tomography (PET/CT) Systems provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Of these devices, seven are in active development, while the remaining five are in an inactive stage of development. There are four products in the early stages of development, and the remaining three are in the late stages of development.

Diagnostic imaging devices are used for the visualization of structural and functional patterns of organs or tissues. Computed Tomography (CT) Systems, Mammography Equipment, MRI Systems, Nuclear Imaging Equipment, Ultrasound Systems, X-ray Systems, Bone Densitometers, Angio Suites, Contrast Media Injectors, Accessories, Contrast Agents, Radiopharmaceuticals and C-arms are covered under this market. PET-CT or PET/CT is a medical imaging technique using a device which combines in a single gantry system both a positron emission tomography (PET) scanner and an x-ray computed tomography (CT) scanner, so that images acquired from both devices can be taken sequentially, in the same session, and combined into a single superposed (co-registered) image. The functional imaging obtained by PET, which depicts the spatial distribution of metabolic or biochemical activity in the body can be more precisely aligned or correlated with anatomic imaging obtained by CT scanning. Two- and three-dimensional image reconstruction may be rendered as a function of a common software and control system. The device consists of a detector, gantry system, transmission source, computer workstation and software.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Positron Emission Tomography/Computed Tomography (PET/CT) Systems pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of Positron Emission Tomography/Computed Tomography (PET/CT) Systems devices. Overall, most of these Positron Emission Tomography/Computed Tomography (PET/CT) Systems pipeline devices are being developed by private entities.

Key players involved in the active development of Positron Emission Tomography/Computed Tomography (PET/CT) Systems include Philips Healthcare, Positron, QUIBIM, Shanghai United Imaging Healthcare, Siemens Healthineers, University of California Davis, University of California Los Angeles, ZumaTek, Emory University and Emory University.

For a complete picture of the developmental pipeline for Positron Emission Tomography/Computed Tomography (PET/CT) Systems devices, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.